The accumulation of advanced glycation end products is thought to be a key factor in the initiation and progression of diabetic nephropathy. Here we determined whether the size of the ligands for the receptor for advanced glycation end products (RAGEs) that were present in the serum of patients with type 2 diabetes modulates their pathogenic potential. Serum was collected from control subjects and patients with type 2 diabetes with varying degrees of renal disease (normo-, micro-, or macroalbuminuria). The titers of the RAGE ligands N-carboxymethyllysine (CML), S100A, S100B, and high-mobility group box 1 (HMGB1) were measured by enzyme-linked immunosorbent assay in serum as well as in pooled size-fractionated serum. We also measured cellular binding of serum fractions to mesangial cells transfected with RAGE and examined the downstream signaling pathways. Circulating CML was increased in patients with type 2 diabetes, whereas HMGB1 was decreased. S100A8, S100BA9, and soluble RAGE were unchanged. The high-molecularweight (over 50 kDa) serum fraction contained the greatest proportion of RAGE ligands, with all immunoreactivity and cellular binding observed only with serum fractions over 30 kDa. High-molecular-weight serum from macroalbuminuric patients showed greater RAGE binding capacity, modulation of cell-surface RAGE expression, increased phospho-protein kinase C-a, and p65 nuclear factor jB DNA-binding activity, which were competitively inhibited by soluble RAGE or CML neutralizing antibodies. These data show that ligands that activate RAGE present in the circulation of patients with type 2 diabetes and nephropathy are predominantly of high molecular weight.
The accumulation of advanced glycation end products is thought to be a key factor in the initiation and progression of diabetic nephropathy. Here we determined whether the size of the ligands for the receptor for advanced glycation end products (RAGEs) that were present in the serum of patients with type 2 diabetes modulates their pathogenic potential. Serum was collected from control subjects and patients with type 2 diabetes with varying degrees of renal disease (normo-, micro-, or macroalbuminuria). The titers of the RAGE ligands N-carboxymethyllysine (CML), S100A, S100B, and high-mobility group box 1 (HMGB1) were measured by enzyme-linked immunosorbent assay in serum as well as in pooled size-fractionated serum. We also measured cellular binding of serum fractions to mesangial cells transfected with RAGE and examined the downstream signaling pathways. Circulating CML was increased in patients with type 2 diabetes, whereas HMGB1 was decreased. S100A8, S100BA9, and soluble RAGE were unchanged. The high-molecularweight (over 50 kDa) serum fraction contained the greatest proportion of RAGE ligands, with all immunoreactivity and cellular binding observed only with serum fractions over 30 kDa. High-molecular-weight serum from macroalbuminuric patients showed greater RAGE binding capacity, modulation of cell-surface RAGE expression, increased phospho-protein kinase C-a, and p65 nuclear factor jB DNA-binding activity, which were competitively inhibited by soluble RAGE or CML neutralizing antibodies. These data show that ligands that activate RAGE present in the circulation of patients with type 2 diabetes and nephropathy are predominantly of high molecular weight.
Diabetic nephropathy is the most common cause of endstage renal disease in developed countries, with a key contributing factor to its development and progression being the accumulation of advanced glycation end products (AGEs). 1 AGEs are a class of complex, heterogeneous compounds formed as the result of nonenzymatic biochemical reactions, including the Maillard reaction, 2 whose accumulation is accelerated in the presence of hyperglycemia and oxidative stress. 3 One of the most commonly identified AGEs present in serum from patients with diabetes 4 and in renal disease 5 is the nonfluorescent modification of lysine, N-carboxymethyllysine (CML), common on circulating proteins such as albumin. Indeed, tissue concentrations of CML have been reported to be predictive of diabetic complications in humans. 6 Furthermore, therapies to decrease tissue concentrations of CML appear to be renoprotective in animal models of diabetic nephropathy. [7] [8] [9] [10] AGEs can exert their biological effects in a number of ways, including modulation of the receptor for advanced glycation end products (RAGE). RAGE, a member of the immunoglobulin superfamily, is a pattern recognition receptor that binds various ligands, including S100/calgranulins, 11 high-mobility group box 1 (HMGB1), 12 and b-amyloid sheets, 13 and is involved in host-pathogen defense. Recently, it has been postulated that the various pathways downstream of RAGE, such as those involving nuclear transcription factor kB (NF-kB), 14 can be activated by multimeric or protein complexes of these ligands. 15 Furthermore, in mouse models of diabetes, genetic overexpression of RAGE leads to a decline in kidney function and renal structural damage, 16 which is attenuated by therapies such as OPB-9195, which lower CML accumulation. Conversely, mice with a genetic deletion of RAGE appear to be protected against the development of diabetic nephropathy. 17, 18 The purpose of this study was to identify the pathogenic potential of circulating RAGE ligands present in type 2 diabetic individuals with varying stages of renal dysfunction. Table 1 summarizes key clinical characteristics of the diabetic patients from whom the serum samples were obtained, stratified by urinary albumin excretion rate (AER). There was no difference in the glomerular filtration rate, age, duration of clinically diagnosed type 2 diabetes, HbA 1C , body mass index, or lipid profile. The male/female ratio was 54-46%.
RESULTS

Patient clinical characteristics
Control serum was obtained from 10 volunteers who were recruited from within our laboratory and from within the Baker IDI Heart & Diabetes Institute Gene Bank. The mean age was 48 ± 18 years, body mass index 26 ± 5 kg/m 2 , 60% were women, and AER was 6±8 mg/min.
Circulating RAGE ligands are heterogeneous in diabetes
Patients with diabetes had an increase in circulating CML concentrations when compared with control subjects (Figure 1a ). There was no change in serum S100A (Figure 1b ) or S100B (Figure 1c ) in diabetic patients. In contrast, circulating HMGB1 was decreased in patients with diabetes when compared with control subjects (Figure 1d ), whereas serum soluble RAGE (sRAGE) was unchanged (Figure 1e ).
RAGE ligands are only present in high-molecular-weight fractions derived from human serum RAGE ligands were next measured in size-fractionated samples from pooled serum. Protein-bound CML was only detected in serum fractions greater than 30 kDa in both control and diabetic patients (Figure 2a ). In addition, CML content was significantly greater in high-molecular-weight fractions (450 kDa) from diabetic sera when compared with control sera (Figure 2a ). Circulating S100A (Figure 2b ) and S100B (Figure 2c ) proteins were only present in serum fractions of greater than 50 kDa. HMGB1 was detected in the 30-50 kDa fraction derived from the control pool and the high-molecular-weight (450 kDa) fraction from control and diabetic patients, with the control fraction containing more HMGB1 protein than that of the diabetic serum fraction (Figure 2d ). Western immunoblotting of serum under nonreduced conditions confirmed that S100B (Figure 2e ) and HMGB1 ( Figure 2f ) were indeed present in the circulation as high-molecular-weight proteins, and that HMGB1 appeared to increase in the diabetic patients in parallel with degree of albuminuria. To investigate further, we performed SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using reduced serum, and revealed the presence of an HMGB1 protein complex at approximately 40 kDa (Figure 2g ), which was absent in the control pool, whereas a 70-kDa protein complex was common to all groups. As RAGE has been recently associated with IgG and HMGB1, western immunoblotting of serum under nonreduced conditions confirmed that IgG was also present at the same molecular weight (Supplementary Figure S1 , Supplementary Online Appendix).
The RAGE-binding capacity of 125 I-radiolabeled serum fractions from control and diabetic patients (with known nephropathy-pooled from micro-and macroalbuminuric patients) was next examined in primary renal mesangial cells overexpressing human full-length RAGE. High-molecularweight serum fractions (450 kDa) from both diabetic and control individuals had significantly increased cellular binding to RAGE overexpressing cells (Figure 2h ) when compared with medium-molecular-weight (MMW) serum fractions (30-50 kDa, containing minimal RAGE ligands). There was no binding to RAGE overexpressing cells detected in other serum fractions (data not shown). Cellular binding of high-molecular-weight serum fractions after stratification for albuminuria was next studied in primary rat mesangial cells overexpressing either human RAGE (AdRAGE) in the presence or absence of soluble RAGE (AdsRAGE). Modified albumin is abundant in high-molecular-weight serum pools derived from patients with diabetes
Non-fractioned and serum pools fractionated by molecular weight from control (À) and diabetic ( þ ) patients (with micro-and macroalbuminuria, pooled) were subjected to SDS-PAGE under reducing conditions (Figure 3a ). CMLmodified bovine serum albumin (BSA) (CML-BSA) was used as a positive control (far right-hand lane). The serum pool from diabetic patients contained a number of highmolecular-weight protein bands, which were not prominent in the control pool ( Figure 3a) . Indeed, immunoblotting revealed that serum albumin from patients with diabetes and albuminuria contained a significantly greater number of CML modifications ( Figure 3b ). The specific ion spray spectra (Figure 3d-f) showed that there was a prominent peak present as part of the albumin spike at approximately 73-78 kDa, which was not evident in the serum pools from control individuals (Figure 3d ). Furthermore, this spike was also identified in the spectrum of CML-modified BSA (Figure 3c ), used as a positive control. Ion spray spectra from diabetic patients with micro-and macroalbuminuria contained the same peak (Figure 3e and f).
High-molecular-weight ligands present in diabetic serum modulate renal mesangial cell RAGE expression and signaling
To investigate if the high-molecular-weight fraction isolated from serum of healthy individuals or patients with type 2 diabetes can induce pathogenic changes in vitro, we exposed primary renal mesangial cells to high-molecular-weight serum fractions for 7 days. The high-molecular-weight serum treatment was equivalent to 100 mg/ml CML-BSA, as measured previously by enzyme-linked immunosorbent assay (ELISA). In addition to high-molecular-weight serum treatment, cells were treated with or without plant-derived sRAGE (1 mg/ml) or a neutralizing CML antibody (1 mg/ml). There was no change in cell-surface RAGE expression on mesangial cells after exposure to high-molecular-weight serum fractions from diabetic patients when compared with control subjects (Figure 4a and b) . However, cell-surface RAGE expression increased when cells were exposed to highmolecular-weight serum fractions derived from patients with macroalbuminuria when compared with those with normoalbuminuria, (Figure 4a ) which was prevented by either sRAGE or CML neutralizing antibodies. When sRAGE was coincubated with high-molecular-weight serum fractions derived from normoalbuminuric patients, there was a modest increase in cell-surface RAGE expression compared with the nontreated normoalbuminuric group (Figure 4a ). The effect of high-molecular-weight fractions on NF-kB DNA-binding activity in renal mesangial cells was determined. There was increased activation of the p65 subunit of NF-kB in mesangial cells exposed to high-molecular-weight serum fractions derived from both microalbuminuric and, to a greater extent, macroalbuminuric patients when compared with control subjects (Figure 4c and d) , which were (Figure 4c ) or a CML neutralizing antibody (Figure 4d) . Administration of sRAGE increased the activation of the p65 subunit of NF-kB in mesangial cells exposed to highmolecular-weight serum from control and diabetic individuals with normo-and microalbuminuria (Figure 4c ).
There was a decrease in the secretion of vascular endothelial growth factor from primary mesangial cells treated with high-molecular-weight serum fractions from diabetic patients with micro-and macroalbuminuria when compared with normoalbuminuric or control individuals (Figure 4e and f) , which was unaffected by sRAGE.
Neutralization of CML with an antibody further decreased the secretion of vascular endothelial growth factor from cells exposed to high-molecular-weight serum from patients with macroalbuminuria ( Figure 4f) .
A key downstream signaling molecule of RAGE in the kidney is protein kinase C (PKC). There was no change in plasma membranous PKC activity in mesangial cells exposed to high-molecular-weight serum fractions derived from patients with diabetes (data not shown). However, phosphorylated PKC-a/total PKC-a ratio was increased in mesangial cells exposed to high-molecular-weight serum fractions from diabetic patients with normo-, micro-, and macroalbuminuria and was attenuated with sRAGE treatment (Figure 5a and b) .
DISCUSSION
Antagonism of the RAGEs is a target under active investigation for the treatment of diabetic complications in humans (http://www.clinicaltrials.gov/ct2/show/NCT00287183?term= NCT00287183&rank=1). Although a number of previous studies have assessed both circulating RAGE ligands and sRAGE concentrations in human cohorts of diabetic nephropathy, conflicting data have been reported. [19] [20] [21] For the first time, in this study, we have not only directly analyzed the levels of various RAGE ligands but have also identified that their pathogenic potential may be greatest when they are part of the high-molecular-weight multimeric structures or are associated with proteins. Furthermore, it is evident that there are disparate effects of these high-molecular-weight ligands in human serum on RAGE-dependent downstream signaling pathways, such as PKC-a and p65 NF-kB, dependent on the degree of renal dysfunction present.
In this study, we identified that almost all of the immunoreactivity for the RAGE ligands studied, namely HMGB1, S100A, S100B, and CML, was present within molecular weight fractions of greater than 50 kDa. For S100/ calgranulins, a previous study has shown that these molecules form multimeric structures to ligate with RAGE, although these studies were not performed in the diabetic context. 22 Other previous work has suggested that circulating HMGB1 is bound with DNA fragments (CpG-A ODN) from necrotic cells and immune complexes in patients with systemic lupus erythematosus, which facilitates and enhances the binding of HMGB1 to RAGE. 15 Indeed, our these data are the first to suggest that HMGB1 exists in serum of diabetic patients in concert with other proteins. Not surprisingly, there was no immunoreactivity for HMGB1 observed in serum fractions of less than 30 kDa in type 2 diabetic patients. In addition, western immunoblots of non-fractioned serum under nonreducing conditions confirmed that HMGB1 protein in the circulation of diabetic patients exists mostly as a complex of greater than 100 kDa. Binding of HMGB1 to circulating immune complexes may selectively switch HMGB1 binding from Toll-like receptors 2 and 4 to RAGE as has been reported in systemic lupus erythematosus. 15 Interestingly, the total serum concentrations of HMGB1, which are almost exclusively high-molecular-weight within this study and IgG associated, are actually decreased in the serum of diabetic patients when compared with controls. This is in contrast to recent study that found increased circulating concentrations of HMGB1 in diabetic patients, 23 though these patients had type 1 diabetes. In this study, however, when serum was separated by SDS-PAGE the complexed HMGB1 appeared to be increased in diabetic patients with renal disease. Moreover, separation of chemically reduced serum samples revealed the appearance of an HMGB1 protein band at approximately 40 kDa, which was absent in the control participants. This may indicate the existence of an alternate complex, though this was not associated with the degree of albuminuria, and the role of this complex in the kidney cannot be deduced by this study.
Hence, because the serum concentrations of S100/ calgranulins also appear to be decreased in diabetic patients, it is more likely that the source of RAGE stimulation and signaling by PKC-a and p65 observed within this study with micro-and macroalbuminuric serum is by other RAGE ligands such as CML-modified proteins including albumin. Indeed, we identified increases in CML modification of albumin in serum from type 2 diabetic patients. This is further supported by our findings that these specific pathways were blocked not only by sRAGE, which acts as a decoy for ligand binding, but also with anti-CML antibodies.
In type 2 diabetes, other studies have suggested that modification of circulating serum albumin is an important contributor to the pathogenesis of complications such as renal disease. 24, 25 Indeed, in our control sera there appears to be minimal modification of the albumin present when compared with that seen in sera from diabetic subjects, consistent with findings from other investigators. 26 However, our data indicate that not only is albumin heavily modified (increasing its molecular weight) but also that a large majority of these modifications are related to CML, with an almost identical albumin spectral peak identified in these patients' sera as that observed in exogenously prepared CMLmodified BSA. It is likely that not only is the CML-modified albumin increased in serum from macroalbuminuric patients but also that this process may also affect the catabolism and turnover of albumin in these patients, shifting albumin from the extravascular to the vascular compartment and thereby prolonging the source of RAGE stimulation.
Our current data show that high-molecular-weight serum fractions had significantly increased cellular binding to RAGE-overexpressing cells when compared with MMW serum fractions containing minimal RAGE ligands. There was no binding to RAGE-overexpressing cells detected in other serum fractions. It is well recognized that larger proteins contain more binding sites than smaller proteins and thereby could theoretically display a higher affinity for ligand binding to RAGE. Indeed, the RAGE ligands studied, CML, S100A and S100B, and HMGB1, are polyvalent ligands. HMGB1 also binds to Toll-like receptor 2 and Toll-like receptor 4.
27 S100A8 (calgranulin A) and S100A9 (calgranulin B) seem to bind and activate various cell-surface receptors such as heparan sulfate proteoglycans, CD36, and RAGE. 28 It has been proposed that multimeric forms of S100 proteins trigger aggregation of RAGE, thereby activating intracellular signaling cascades. 28 Not only does our study show a greater binding capacity of high-molecular-weight serum to RAGE, but it also provides evidence that serum fractions from patients with renal disease bind RAGE, and perhaps have a higher affinity for RAGE, more than serum fractions from patients without renal disease. Moreover, these fractions are functionally active as shown by our in vitro studies in primary mesangial cells.
The differential effects of circulating RAGE ligands present within the serum of type 2 diabetic patients with varying degrees of renal dysfunction highlight the importance of investigating temporal changes in pathogenic mediators during the development of a chronic disease such as diabetic nephropathy. One would suggest that these findings are directly relevant for the design of antagonists for this multiligand receptor, because the circulating RAGE ligands with the most pathogenic potential identified in this study were all complex structures, being multimeric or proteinassociated and therefore of high molecular weight. It appears that the use of RAGE antagonists in individuals with macroalbuminuria as a result of type 2 diabetes are likely to be most helpful and should be considered a novel rational approach to treat this disorder.
MATERIALS AND METHODS
An expanded version of the 'research design and methods' is available in Supplementary Online Appendix containing details of SDS-PAGE, western immunoblotting, ion trap LC-MS/MS, cell lysate preparation, 125 I radioligand binding assay, flow cytometry, PKC activity, vascular endothelial growth factor, ELISA, and NF-kB DNA-binding activity. Patient sample collection Serum samples were drawn from a collection of type 2 diabetic patients with varying degrees of albuminuria and compared with matched control patients. Patients were classified as normoalbuminuric (normo, AERo20 mg/min), microalbuminuric (micro, AER 20-200 mg/min), or macroalbuminuric (macro, AER X200 mg/min). The glomerular filtration rate was measured isotopically using 99 Tc-DTPA and was expressed per 1.73 m 2 of body surface area. Fasting lipids were measured by enzymatic colorimetry. Total cholesterol was measured by enzymatic colorimetric methods, and low-density lipoprotein-cholesterol was calculated using the Friedewald equation. As the primary referral base for these participants was from general practitioners, with only 20% referred directly from within the hospital, the cohort is considered representative of the general diabetes population. Blood and urine were collected as part of routine examination, with albumin excretion rate determined from a 24 h urine collection and HbA 1C each assayed at the time of sample collection. All procedures were in accordance with the Declaration of Helsinki Principles and were approved by the Austin Health Human Ethics Committee. Control serum was obtained from 10 volunteers who were recruited from within the laboratory and from within the Baker IDI Heart & Diabetes Institute Gene Bank.
Size fractionation of serum samples Sera were pooled and enriched for specific molecular weight fractions using Amicon Ultra-15 Centrifugal Filter devices (Millipore, Bedford, MA, USA). Briefly, 15 ml of serum from control (serum from n ¼ 10 patients, pooled), normoalbuminuric (n ¼ 84 patients pooled), microalbuminuric (n ¼ 84 patients pooled), or macroalbuminuric (n ¼ 35 patients pooled) patients were added to a 50-kDa molecular weight cutoff filter column and centrifuged for 3000g for 1 h. The concentrate was collected (450 kDa fraction, high molecular weight) and the ultrafiltrate was transferred to a 30-kDa molecular weight cutoff filter column and centrifuged for a further 10 min at 3000g. The concentrate was collected (30-50 kDa fraction, MMW) and the ultrafiltrate was transferred to a 5-kDa molecular weight cutoff filter column and centrifuged for 40 min at 3000g. The concentrate (5-30 kDa fraction) and ultrafiltrate (o5 kDa fraction) were collected. These individual serum fractions representing molecular weights o5, 5-30, 30-50, and 450 kDa were stored at À80 1C.
Cell culture
Mesangial cells were isolated from kidneys of Sprague-Dawley rats as previously described. 17 Isolated cells were cultured in Dulbecco's modified Eagle's medium (with no phenol red), supplemented with 2 mmol/l glutamine, 5000 U/ml penicillin/streptomycin, and 20% fetal bovine serum. Cells were passaged weekly for up to 10 passages. For the RAGE expression and signaling studies, mesangial cells were cultured in high glucose conditions (25 mmol/l D-glucose) for 7 days with either control, normo, micro, or macro high-molecular-weight pooled serum prepared as described above. The content of the physiologically relevant AGE, CML, was determined in the highmolecular-weight serum fractions by ELISA as described below. High-molecular-weight serum fractions were administered to cells at a dose equivalent to 100 mg/ml of CML. In addition, cells were treated with or without plant-derived sRAGE (sRAGE) (1 mg/ml) or neutralizing CML antibody (1 mg/ml).
RAGE ligand determination
Out of the total serum samples collected, we randomly sampled 20 serum samples per group in which to determine RAGE ligands.
CML concentrations in total serum and serum fractions were measured by ELISA as previously described. 29 Calgranulins A (S100A8) and B (S100A9) were measured in total serum and in serum fractions using commercially available MRP8 (for calgranulin
